| [1] |
Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on Endocrine Hypertension of The European Society of Hypertension[J]. J Hypertens, 2020, 38:1919-1928.
|
| [2] |
Nanba K, Baker JE, Blinder AR, et al. Histopathology and genetic causes of primary aldosteronism in young adults[J]. J Clin Endocrinol Metab, 2022, 107:2473-2482.
|
| [3] |
Pitsava G, Faucz FR, Stratakis CA, et al. Update on the genetics of primary aldosteronism and aldosterone-produc-ing adenomas[J]. Curr Cardiol Rep, 2022, 24:1189-1195.
|
| [4] |
Yang Y, Gomez-Sanchez CE, Jaquin D, et al. Primary aldosteronism: KCNJ5 mutations and adrenocortical cell growth[J]. Hypertension, 2019, 74:809-816.
|
| [5] |
Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells[J]. J Clin Endocrinol Metab, 2012, 97:E1567-E1572.
|
| [6] |
Oki K, Gomez-Sanchez CE. The landscape of molecular mechanism for aldosterone production in aldosterone-producing adenoma[J]. Endocr J, 2020, 67:989-995.
|
| [7] |
Prakriya M. Calcium and cell function[J]. J Physiol, 2020, 598:1647-1648.
|
| [8] |
Williams TA, Monticone S, Crudo V, et al. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis[J]. Hypertension, 2012, 59:833-839.
|
| [9] |
Su H, Gu Y, Li F, et al. The PI3K/AKT/mTOR signaling pathway is overactivated in primary aldosteronism[J]. PLoS One, 2013, 8:e62399. doi:10.1371/journal.pone.0062399
|
| [10] |
Williams TA, Monticone S, Morello F, et al. Teratocarcinoma-derived growth factor-1 is upregulated in aldosterone-producing adenomas and increases aldosterone secretion and inhibits apoptosis in vitro[J]. Hypertension, 2010, 55:1468-1475.
|
| [11] |
Backman S, Åkerström T, Maharjan R, et al. RNA Sequencing provides novel insights into the transcriptome of aldosterone producing adenomas[J]. Sci Rep, 2019, 9:6269. doi:10.1038/s41598-019-41525-2.
|
| [12] |
Lefèvre L, Omeiri H, Drougat L, et al. Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma[J]. Oncogenesis, 2015, 4:e161. doi:10.1038/oncsis.2015.20.
|
| [13] |
Oki K, Plonczynski MW, Gomez-Sanchez EP, et al. YPEL4 modulates HAC15 adrenal cell proliferation and is associated with tumor diameter[J]. Mol Cell Endocrinol, 2016, 434:93-98.
|
| [14] |
Shaikh LH, Zhou J, Teo AE, et al. LGR5 activates noncanonical wnt signaling and inhibits aldosterone production in the human adrenal[J]. J Clin Endocrinol Metab, 2015, 100:E836-E844.
|
| [15] |
Maniero C, Garg S, Zhao W, et al. NEFM (Neurofila-ment Medium) polypeptide, a marker for zona glomeru-losa cells in human adrenal, inhibits D1R (dopamine D1 receptor)-mediated secretion of aldosterone[J]. Hypertension, 2017, 70:357-364.
|
| [16] |
El Zein RM, Soria AH, Golib Dzib JF, et al. Retinoic acid receptor α as a novel contributor to adrenal cortex structure and function through interactions with wnt and vegfa signalling[J]. Sci Rep, 2019, 9:14677. doi:10.1038/s41598-019-50988-2.
|
| [17] |
Belavgeni A, Bornstein SR, von Mássenhausen A, et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis[J]. Proc Natl Acad Sci U S A, 2019, 116:22269-22274.
|
| [18] |
Yang Y, Tetti M, Vohra T, et al. BEX1 is differentially expressed in aldosterone-producing adenomas and protects human adrenocortical cells from ferroptosis[J]. Hypertension, 2021, 77:1647-1658.
|
| [19] |
Gong S, Tetti M, Reincke M, et al. Primary aldosteronism: metabolic reprogramming and the pathogenesis of aldosterone-producing adenomas[J]. Cancers (Basel), 2021, 13. doi:10.3390/cancers13153716.
|
| [20] |
Murakami M, Yoshimoto T, Nakabayashi K, et al. Integration of transcriptome and methylome analysis of aldosterone-producing adenomas[J]. Eur J Endocrinol, 2015, 173:185-195.
|
| [21] |
He J, Cao Y, Su T, et al. Downregulation of miR-375 in aldosterone-producing adenomas promotes tumour cell growth via MTDH[J]. Clin Endocrinol (Oxf), 2015, 83:581-589.
|
| [22] |
Peng KY, Chang HM, Lin YF, et al. miRNA-203 modulates qldosterone levels and cell proliferation by targeting wnt5a in aldosterone-producing adenomas[J]. J Clin Endocrinol Metab, 2018, 103:3737-3747.
|
| [23] |
Zhang G, Zou X, Liu Q, et al. MiR-193a-3p functions as a tumour suppressor in human aldosterone-producing adrenocortical adenoma by down-regulating CYP11B2[J]. Int J Exp Pathol, 2018, 99:77-86.
|
| [24] |
Fu R, Walters K, Kaufman ML, et al. In situ spatial reconstruction of distinct normal and pathological cell populations within the human adrenal gland[J]. J Endocr Soc, 2023, 7:bvad131. doi:10.1210/jendso/bvad131.
|
| [25] |
Motomura N, Yamazaki Y, Gao X, et al. Visualization of calcium channel blockers in human adrenal tissues and their possible effects on steroidogenesis in the patients with primary aldosteronism (PA)[J]. J Steroid Biochem Mol Biol, 2022, 218:106062. doi:10.1016/j.jsbmb.2022.106062.
|
